Gallbladder cancer (GBC) is a highly malignant bile duct cancer with poor prognosis characterized by its insensitivity to chemotherapy. Emerging evidence indicates that cytoprotective antioxidation is involved in drug resistance of various cancers; however, the underlying molecular mechanisms remain obscure. Here, we demonstrated that atypical protein kinase Cι (aPKCι) mediated reactive oxygen species (ROS) inhibition in a kinase-independent manner, which played a crucial role in tumorigenesis and chemoresistance. Mechanistically, we found that aPKCι facilitated nuclear factor erythroid 2-related factor 2 (Nrf2) accumulation, nuclear translocation and activated its target genes by competing with Nrf2 for binding to Kelch-like ECH-associated protein 1 (Keap1) through a highly conserved DLL motif. In addition, the aPKCι-Keap1 interaction was required for antioxidant effect, cell growth and gemcitabine resistance in GBC. Importantly, we further confirmed that aPKCι was frequently upregulated and correlated with poor prognosis in patients with GBC. Collectively, our findings suggested that aPKCι positively modulated the Keap1-Nrf2 pathway to enhance GBC growth and gemcitabine resistance, implying that the aPKCι-Keap1-Nrf2 axis may be a potential approach to overcome the drug resistance for the treatment of GBC.
Introduction
Gallbladder cancer (GBC), a primary malignancy of the biliary tract, is the sixth most common gastrointestinal cancer and has a 5-year survival rate of 5% [1, 2] . Although radical resection is the most promising potential curative approach for patients, less than 10% of patients are considered candidates for resection because of advanced stage disease [3, 4] . Gemcitabine has been widely used for the treatment of GBC; however, the response rate of only 36% leaves much to be desired [5] . Therefore, it is urgently required to identify the molecular mechanisms responsible for chemotherapy resistance in GBC.
Maintenance of reactive oxygen species (ROS) homeostasis is essential for cell survival. In recent years, growing evidence shows that ROS dysregulation is involved in the development of multiple diseases, including cancers [6, 7] . In order to survive in complex internal and external environments, cancer cells have developed effective antioxidant system to limit the excessive accumulation of ROS [8] . Indeed, conventional chemotherapeutic drugs often utilize elevated ROS to eliminate cancer cells [9] . The upregulation of antioxidant capacity in cancer cells can confer drug resistance. Thus, dissecting such drug-resistant molecular mechanisms may be potential therapeutic targets to overcome the resistance.
The Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid-2-related factor 2 (Nrf2) complex is the major regulator of cytoprotective responses to endogenous and exogenous stresses caused by ROS and electrophiles [10] . Nrf2, as the key signaling protein of the pathway, mediates the expression of a series of oxidative stress-related genes that maintain cellular redox balance [11] . Under normal physiological conditions, Nrf2 activity is tightly regulated by Keap1 and promoted its ubiquitin-dependent proteasomal degradation in the cytoplasm; however, oxidative stresses prevent the Keap1-induced degradation of Nrf2, which leads to Nrf2's accumulation, nuclear translocation and subsequently transcriptional activation of its downstream target genes such as heme oxygenase 1 (HMOX1), NADPH quinone oxidoreductase 1 (NQO1), and glutamate-cysteine ligase (GCL) [12] . Recent studies suggest that the dysfunctional Keap1-Nrf2 interaction may be involved in drug metabolism and increasing the resistance to chemotherapy [10] . However, the precise molecular mechanisms underlying the Keap1-Nrf2 pathway and chemoresistance remain largely unknown.
Atypical protein kinase Cι (aPKCι), one of the protein kinase C (PKC) isozymes, has emerged as an important oncogene in various cancers [13] . We previously demonstrated that aPKCι was overexpressed and correlated with poor clinical outcome in cholangiocarcinoma (CCA) and drove CCA cells invasion and metastasis in vitro and in vivo [14] . Moreover, aPKCι was also found to function in conferring resistance to chemotherapy of human leukemia cells [15] . The above reports have expanded the concept that aPKCι is a particularly attractive therapeutic target for cancer treatment. Unfortunately, how aPKCι functions in GBC has not been extensively studied.
In this study, we found that a previously unknown fundamental function of aPKCι is to compete with Nrf2 for binding to Keap1. We further demonstrated that aPKCι-Keap1-Nrf2 signaling is critical for promoting cell tumorigenesis and gemcitabine resistance in GBC.
Materials and methods

Cell lines
Human GBC cell lines NOZ and GBC-SD were generously provided by Prof. Yingbin Liu, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, China. These cells were maintained in William's medium or RPMI 1640 (both from Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco), respectively. All cell lines were authenticated, mycoplasma-free and cultured at 37°C in a humidified incubator containing 5% CO 2 .
Plasmids construction
The pFlag-PRKCI and pMyc-Keap1 plasmids were purchased from ViGene Biosciences (Shandong, China). All 5 truncated Keap1 mutants were constructed as previously described [16] . The PRKCI and Keap1 deletion mutants were subcloned into the pENTER vector using an appropriate restriction enzyme. Site-directed mutagenesis was performed to generate DLL 257 , DLM 341 and DLK 380 mutants of PRKCI by using the QuickMutation™ Kit (Beyotime, Hangzhou, China) with fulllength PRKCI expressing plasmid as a template. The plasmids used in this study are listed in Supplementary Table S1 . All mutants were validated by sequencing.
Western blotting
Briefly, cells or tissues were lysed by ice-cold RIPA Lysis Buffer plus protease and a phosphatase inhibitor cocktail (Beyotime, Hangzhou, China). The cytoplasmic and nuclear fractions were isolated from cells by using the Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime, Hangzhou, China) according to the manufacturer's protocol. Equal amount of proteins were analyzed on 10% SDS-PAGE gels. β-actin was used as a loading control for cytoplasmic fraction, whereas LaminB was used as a loading control for the nuclear fraction. All blots were visualized by ECL (Boster, Wuhan, China). The intensity of bands was evaluated by Image Lab (Bio-Rad, California, USA). The experiments were repeated independently for three times. The antibodies used in this study are listed in Supplementary Table S2 .
Co-immunoprecipitation
Co-immunoprecipitation (Co-IP) assay was performed to analyze protein-protein interactions. In brief, the cells were lysed by RIPA buffer and divided into parallel groups named input or IPs. Then, the primary antibody or IgG was added to the lysates for incubation overnight at 4°C. Subsequently, the Protein A + G agarose beads were added to the mixture at 4°C for 3 h. After centrifugation at 15,000×g for 15 min, the beads were collected and washed 5 times with RIPA buffer. The immunoblotting was performed with the indicated antibodies as previously reported.
Patients and specimens
In total, 72 human GBC tissues and paired normal gallbladder tissues (5 cm distant from tumor) were collected from patients undergoing resection at the Department of Biliary and Pancreatic Surgery, Tongji Hospital (Wuhan, China) between January 2009 and December 2016. Ethical approval for the use of human samples was obtained from the Tongji Hospital Research Ethical Committee. None of the patients had received any adjuvant therapy before surgery. All cases were diagnosed by two independent pathologists. The GBC samples were staged according to the 7th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual. The detailed clinicopathological characteristics of the 72 patients with GBC are listed in Supplementary  Table S3 .
Immunohistochemistry (IHC)
GBC samples or xenograft tumor tissues were fixed in 4% paraformaldehyde, paraffin embedded, and sectioned. The expression of aPKCι, Nrf2 and Keap1 was detected by immunohistochemistry as previously reported [17] . The positively stained cells were scored, with scores ranging from 0 to 12. The total score ≤4 was considered as low expression and > 4 as high expression [18] .
Animal study
Six-week-old female BALB/c-nude mice were used in all animal experiments and housed under specific pathogen-free (SPF) conditions in Central Animal Laboratory, Tongji Medical College. For the first animal experiment, 20 mice were randomly divided into four groups (n = 5 per group). A total of 2 × 10 6 NOZ cells transfected with lentivirus empty vector, aPKCι overexpression, si-neg, or si-aPKCι vectors were injected subcutaneously in the upper back of mice, respectively. For the second animal experiment, the same number of mice were randomly divided into 2 groups (n = 10 per group). A total of 2 × 10 6 NOZ cells transfected with lentiviral si-neg or si-aPKCι vectors were injected subcutaneously in the upper back of mice, respectively. One week later, each group was randomly regrouped two subgroups (n = 5 per group) to receive intraperitoneal injection of gemcitabine (15 mg/ kg) or 0.9% sodium chloride (NS) every 3 days. The diameter of tumors and the weight of the mice were measured every 3 days. The volume of tumors was calculated using the formula: 1/2 (length × width 2 ). All mice were sacrificed 3 weeks later, and the tumors were dissected out for immunohistochemistry, western blot assay or quantitative real-time PCR (qPCR). All animal experiments were conducted according to the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines and were approved by the Committee on the Ethics of Animal Experiments of the Tongji Medical College, HUST.
Additional experimental procedures are provided in detail in the Supplementary data. SPSS, Armonk, NY, USA) or GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA). The results were presented as mean ± standard deviation (SD). Quantitative data were analyzed by two-tailed independent Student's t tests and analysis of variance. Categorical variables were compared using chi-square tests or Fisher exact tests. Clinical correlations were analyzed using χ 2 tests, and survival analysis was conducted by the Kaplan-Meier method with log-rank tests. Differences with P values of less than 0.05 were considered statistically significant.
Results
aPKCι inhibits ROS in a kinase-independent manner
To investigate a possible functional link between aPKCι and ROS, we first stably established ectopic aPKCι expression or knockdown GBC Fig. 1 . aPKCι inhibits ROS in a kinase-independent manner. (A-B) qPCR and western blotting were performed to detect the expression levels of aPKCι in NOZ and GBC-SD cells with lentivirus-mediated aPKCι overexpression (aPKCι)/knockdown (si-aPKCι) or re-expression. β-actin was used as a loading control. neg, negative control. N.S. no significance. (C-D) ROS levels were measured by DCFH-DA in GBC cells with the treatment of aPKCι overexpression, knockdown, re-expression or gemcitabine. (E) Protein levels of aPKCι, phosphorylated-Nrf2 (p-Nrf2) and Total Nrf2 (T-Nrf2) were tested in GBC cells after aPKCι overexpression with or without PSI treatments (10 μM). (F) Relative ROS levels were detected in GBC cells after aPKCι overexpression with or without PSI treatments (10 μM). *P < 0.05, **P < 0.01. Data are derived from three independent experiments and presented as means ± SDs. cell lines NOZ and GBC-SD ( Fig. 1A and B ), which were used in the subsequent experiments. The ectopic expression of aPKCι significantly reduced the cellular ROS levels in GBC cells. Conversely, aPKCι silencing triggered the accumulation of ROS. Interestingly, restoring exogenous aPKCι expression reversed the effects of aPKCι knockdown, suggesting that aPKCι may act as an antioxidative factor (Fig. 1C ). Importantly, we further found that aPKCι overexpression also attenuated gemcitabine-induced ROS production. aPKCι deletion elevated the cellular ROS levels under this condition, which was reversed by the expression of exogenous aPKCι (Fig. 1D ). Therefore, these data showed that aPKCι suppressed the intracellular ROS to control cytoprotective response under both normal and oxidative stress conditions. Previous studies indicated that aPKC(s) involved in oxidant stress response by phosphorylation of Nrf2 [19] ; however, we found that aPKCι overexpression significantly changed ROS levels in GBC cells treated with PSI, an aPKC peptide inhibitor, while there was weak and no obvious alteration of phosphorylated Nrf2 ( Fig. 1E and F) . Interestingly, aPKCι overexpression led to significant accumulation of the total Nrf2 protein ( Fig. 1E ). Of note, we also found that PSI reduced the expression levels of phosphorylated aPKCι, but the total aPKCι, phosphorylated Nrf2 and total Nrf2 proteins had no significant change. The phosphorylation of epithelial cell transforming sequence 2 (Ect2), an aPKCι substrate [20, 21] , was indeed inhibited by PSI, while there was no obvious alteration of the total Ect2 protein ( Fig. S1A ). More importantly, we constructed Flag-tagged wild-type (WT), constitutively active catalytic domain (CAT) and kinase-inactive (KI) mutants of aPKCι as previously reported [22] . The data showed that these mutants had minimal impact on the expression levels of phosphorylated Nrf2 (Figs. S1B and C). Together, these results suggest that aPKCι-mediated antioxidant effect was independent of its well-studied kinase function.
aPKCι promotes Nrf2 accumulation and activates antioxidative signaling
Given that the Keap1-Nrf2 complex is the key regulator of antioxidative signaling, we determined whether aPKCι induced ROS inhibition through the Keap1-Nrf2 pathway. Our data showed that aPKCι did not affect the protein expression of Keap1 in GBC cells ( Fig. 2A ). However, ectopic aPKCι expression significantly increased the protein levels of Nrf2. aPKCι knockdown led to reduction in the level of the Nrf2 protein, which was reversed by restoring aPKCι expression ( Fig. 2A) . Interestingly, the mRNA levels of both Keap1 and Nrf2 were not altered by aPKCι expression (Fig. 2B ). These results indicated that aPKCι positively modulated Nrf2 accumulation, and the process did not occur at the transcriptional level.
Next, we further investigated whether aPKCι regulated the intracellular distribution of the Nrf2 protein. Western blotting results showed that aPKCι promoted Nrf2 nuclear location, while aPKCι knockdown prevented the transposition (Fig. 2C ). In contrast, there was no obvious change in the level of the Keap1 protein in both the cytoplasm and nucleus. Previous studies demonstrated that nuclear Nrf2 can bind to the antioxidant response element (ARE) and then activate the downstream genes [23] . To confirm the transcriptional activity of Nrf2, qPCR was performed to detect the mRNA levels of well-established downstream genes such as HMOX1, NQO1, GCLC, GCLM and FTH1. The ectopic aPKCι expression showed an estimated 2.3-3.8 fold increase in GBC cells, whereas aPKCι depletion reduced the expression of these genes by 50% ( Fig. 2D) . Notably, re-expression of aPKCι reversed the effect of aPKCι knockdown. In addition, we further found that aPKCιmediated ROS inhibition can be abolished by Nrf2 knockdown ( Fig. 2E and F). Therefore, Nrf2 is required for aPKCι-induced antioxidative signaling. Collectively, the above findings suggest that aPKCι promotes Nrf2 accumulation, nuclear location, and lowers the ROS levels.
aPKCι competes with Nrf2 for Keap1 binding through the DLL motif
Previous studies have reported that Keap1 could bind with Nrf2 and promote its degradation by the ubiquitin proteasome pathway [24] . In this study, we found that the proteasome inhibitor MG132 completely rescued aPKCι knockdown-induced reduction of Nrf2 ( Fig. 3A and S2A ). The data revealed that aPKCι might inhibit ubiquitin-proteasomemediated degradation of Nrf2. Indeed, we further confirmed that ectopic aPKCι expression significantly reduced the ubiquitination of the endogenous Nrf2 in GBC cells. Conversely, aPKCι knockdown increased the level of ubiqutin-Nrf2 ( Fig. 3B and S2B ). Interestingly, it has also been demonstrated that the degradation of Nrf2 may be induced in a Keap1-independent manner [25] . These observations prompted us to investigate whether aPKCι-induced Nrf2 accumulation is associated with Keap1. The results indicated that Keap1 knockdown did not affect the protein expression of aPKCι, while abolished aPKCι-induced Nrf2 accumulation ( Fig. 3C and S2C ). Moreover, there was no significant alteration of p62 protein, reported as a negative regulator of Keap1, after aPKCι or Keap1 knockdown ( Fig. 3C ). Therefore, we speculated that aPKCι may compete with Nrf2 to bind with Keap1. To validate the hypothesis, we conducted immunoprecipitation experiment to analyze the interaction between aPKCι and the Keap1-Nrf2 complex by using Flag-aPKCι and Keap1-Myc plasmids. Under normal cellular conditions, Flag-aPKCι was immunoprecipitated by Keap1-Myc. Conversely, Keap1-Myc was detected in the Flag-immunoprecipitates ( Fig. 3D ). It has previously been reported that stress-induced reduction of Keap1-Nrf2 was the main mechanism of Nrf2 activation [26, 27] . Thus, we further analyzed whether aPKCι was involved in regulating the process under oxidative stresses induced by gemcitabine. Interestingly, the binding amount of aPKCι and Keap1 proteins was significantly increased, accompanying with a decreased interaction of Keap1and Nrf2 (Fig. 3E  and S2D ). To further validate that aPKCι can compete with Nrf2 for Keap1 binding, in vitro translation and immunoprecipitation experiments were performed. The equal amount of Nrf2 and Keap1 proteins were incubated together with different doses of aPKCι protein. Interestingly, the binding amount of Nrf2 and Keap1 was gradually decreased with an increased interaction of aPKCι and Keap1 (Fig. 3F ). More importantly, aPKCι overexpression reduced, while aPKCι knockdown increased, the Keap1-Nrf2 complex in GBC cells. The Keap1-aPKCι complex exhibited an opposite result ( Fig. S2E and F) . These data suggested that aPKCι disrupted the formation of the Keap1-Nrf2 complex by competing with Nrf2 for Keap1 binding.
Next, we investigated the mechanisms underlying aPKCι-mediated dysregulation of the Keap1-Nrf2 system. Previous studies demonstrated that Nrf2 contained seven functional domains, including ETGE and DLG motifs, which are known as Keap1 binding sites [10] . Besides Nrf2, recent studies have identified other proteins with ETGE or similar motifs that can bind with Keap1 [28] [29] [30] . Indeed, Fukutomi and colleagues demonstrated that the DLG motif needs to be much more extended than the classical motifs [31] . Surprisingly, we found that 252-QDFDLL-257 was highly conserved from chicken to human, as a related DLG motif in Nrf2, within aPKCι. Thus, we generated a series of mutants, in which the QDFDLL was deleted, or DLL motif was changed to DLA. Moreover, two other DLM 341 and DLK 380 motifs were also mutated with DLA (Fig. 3G) . The results indicated that both deletion mutant and DLL 257 mutant were unable to interact with Keap1. However, DLM 341 and DLK 380 mutants have no obvious effect on this interaction ( Fig. 3H) . Therefore, the DLL 257 motif of aPKCι is required for its molecular recognition of Keap1.
To identify the specific regions that are involved in the interaction of aPKCι and Keap1, we performed immunoprecipitation assays with a series of deletion mutants of Keap1 in HEK293T cells. The results showed that the Keap1 N-terminal deletion mutants (D1, D2 and D3) and C-terminal deletion mutant D5 bound with aPKCι, whereas DGR deletion mutant (D4) failed to interact with aPKCι, indicating that the DGR domain is required for Keap1 to bind with aPKCι ( Fig. 3I and J) . It is worth noting that previous studies have identified the DGR domain is essential to maintain the interaction of Keap1 and Nrf2 [32, 33] . These results therefore suggest that aPKCι competes with Nrf2 to bind with Keap1 through the DLL motif.
aPKCι promotes GBC cells tumorigenesis both in vivo and in vitro
Based on the above findings, we sought to further investigate whether aPKCι led to phenotypic changes in GBC cells. The Cell Counting Kit-8 (CCK-8) assay revealed that ectopic aPKCι expression dramatically enhanced the GBC cells proliferation compared with the cells transfected with empty vector. Conversely, aPKCι silencing significantly suppressed the cells proliferation ability, which was reversed by re-expression of aPKCι (Fig. 4A) . Consistently, aPKCι overexpression increased, while aPKCι knockdown inhibited, GBC cells growth as demonstrated by a soft agar growth assay. Recovery of exogenous aPKCι expression eliminated the effect of aPKCι deficiency (Fig. 4B ). In vivo tumorigenicity assays, we further confirmed that the xenograft tumors grew more rapidly in the aPKCι overexpression group than that in the empty vector group. aPKCι depletion reduced the volume and weight of xenograft tumors compared with those of the negative control group (Fig. 4C and D) . Western blotting and immunostaining results confirmed that aPKCι affected the expression of Nrf2, but not Keap1, in xenograft tumors (Fig. 4E and S3A and B ). In addition, Nrf2 mRNA level showed no obvious alteration; however, its target genes mRNA levels, such as HMOX1, NQO1, GCLC, GCLM and FTH1, were significantly increased in the aPKCι overexpression group. Consistently, aPKCι knockdown effectively inhibited the expression of these genes except Nrf2 (Fig. 4F ). Together, our data suggest that aPKCι promotes GBC cells tumorigenesis both in vivo and in vitro. 
aPKCι-mediated ROS inhibition enhances gemcitabine resistance in GBC
Next, we further investigated whether aPKCι would influence the sensitivity of GBC cells to commonly used chemotherapeutic drugs gemcitabine. Given that ROS has been reported to participate in chemoresistance, we speculated that aPKCι may involve in this process. We treated aPKCι or Nrf2 silencing GBC cells with various concentrations of gemcitabine for 72 h to analyze the cell viability by CCK-8 assays. Indeed, when aPKCι was knocked down, the cells exhibited more sensitivity to gemcitabine than the negative control group, with a dramatically decreased of IC50 ( Fig. 5A and S4A) . Then, we examined the viability of the two GBC cell lines with the indicated dose of gemcitabine for 24, 48 and 72 h. The results showed that the sensitivity of the cells to gemcitabine increased with time in the aPKCι knockdown group (Fig. 5B and S4B) . Notably, we also observed similar results that the loss of Nrf2 could help GBC cells to overcome the obstacle of chemoresistance. Moreover, we found that aPKCι or Nrf2 depletion led to ROS accumulation in gemcitabine-treated cells (Fig. 5C and S4C) . Consistently, aPKCι deficiency decreased the Nrf2 protein and its target genes expression levels in cells treated with gemcitabine ( Fig. 5D -E and S4D and E). Furthermore, B-cell lymphoma 2 (Bcl2) protein was decreased, while Bcl-2-associated X (Bax) protein was increased after aPKCι knockdown in GBC cells treated with gemcitabine ( Fig. 5D and  S4D) . In vivo, gemcitabine had slight suppression effect on the growth of xenograft tumors in the negative control group. However, when aPKCι was depleted, the tumors were significantly repressed in the presence of gemcitabine ( Fig. 5F and G) . Therefore, aPKCι improves the resistance of GBC cells to gemcitabine through ROS inhibition.
The DLL motif is required for aPKCι-mediated ROS inhibition, cell growth and gemcitabine resistance
To further validate whether the aPKCι-Keap1 interaction through the DLL motif is associated with these biological functions, aPKCι-WT (wild-type), aPKCι-DLL 257 deletion mutant (M1) and aPKCι-DLL 257 mutant (M2) vectors were transfected into aPKCι-deficient cells. We found that re-expression of aPKCι-WT, but not mutant M1 or M2, reversed the reduction of the level of Nrf2 protein and its target genes induced by aPKCι knockdown (Fig. 6A and B) . In addition, we examined the intracellular ROS levels in aPKCι-deficient cells with the above vectors. As shown in Fig. 6C , mutant M1 or M2 did not reduce the intracellular ROS levels in both NOZ and GBC-SD cells. Likewise, mutant M1 or M2 had no obvious effect on cell growth when aPKCι was silenced (Fig. 6D) . Consistently, aPKCι-WT rescued the defects of cell proliferation in aPKCι-deficient cells treated with gemcitabine; however, transfection with mutant M1 or M2 failed to produce this effect (Fig. 6E) . These results suggest that the aPKCι-Keap1 interaction through the DLL motif is required for cell growth, ROS inhibition, and chemoresistance in GBC cells.
aPKCι is frequently upregulated and correlated with poor prognosis in patients with GBC
Finally, we further investigated the correlation among aPKCι, Nrf2, and Keap1 in 72 GBC specimens. IHC analysis showed that the expression levels of aPKCι and Nrf2 were significantly higher in GBC tissues than in pair-matched normal tissues. There was no obvious alteration of Keap1 expression levels in GBC samples ( Fig. 7A and B) . 77.6% (38 cases) of specimens with higher aPKCι (49 cases) tended to express higher Nrf2, while 65.2% (15 cases) of specimens with lower aPKCι (23 cases) exhibited lower Nrf2. However, there was no significant correlation between aPKCι and Keap1 (Fig. 7C) . Consistently, the upregulation of aPKCι and Nrf2 was further examined at the protein level in representative 8 paired GBC tissues (Fig. 7D ). In addition, we also found that the mRNA levels of Nrf2 target genes increased in GBC tissues (Fig. S5) . The expression level of aPKCι was significantly associated with advanced TNM stage (χ 2 = 19.965, P < 0.001), lymph node metastasis (χ 2 = 13.125, P < 0.001), and poor tumor differentiation (χ 2 = 29.154, P < 0.001) in GBC (Fig. 7E ). Kaplan-Meier analysis indicated that patients with high aPKCι expression exhibited a shorter overall survival (OS) than those with low aPKCι expression ( Fig. 7F ). Multivariate Cox regression analyses indicated that aPKCι expression was an independent prognostic factor for OS in patients with GBC ( Supplementary Table S4 ). Therefore, these observations suggested that aPKCι was frequently upregulated and associated with poor prognosis in patients with GBC. The overexpression of Nrf2 protein and its target genes may be dependent, at least in part, on the elevation of aPKCι in GBC samples.
Discussion
Chemotherapy resistance is a major obstacle to the effective treatment of cancer. Although recent evidence has shown that the elevated expression of aPKCι is correlated with chemoresistance in various human cancers [34] , the molecular mechanisms that drive the enhanced tumorigenic potential and drug resistance of GBC cells remain enigmatic. Here, we provide novel evidence that aPKCι competes with Nrf2 for binding to Keap1, which leads to Nrf2 nuclear accumulation and ROS inhibition in GBC cells (Fig. 8 ). Our data may provide an explanation of how aPKCι exerts oncogenic functions in GBC. In addition, this ability of aPKCι has been further demonstrated to be associated with resistance to gemcitabine in GBC, which is notorious for its insensitivity to chemotherapy.
As a distinct member of the protein kinase C family, aPKCι has been reported to be a particularly attractive therapeutic target for cancer treatment [13, 35] . We and other researchers have demonstrated that aPKCι drove multiple cancer cells invasion and transformed growth in vitro and in vivo [14, 36, 37] . Recent studies also showed that aPKCι maintained a stem-like phenotype in lung squamous cell carcinoma through autonomous Hedgehog (Hh) signaling and served as a potential therapeutic strategy for Hh mutations that confer resistance [38] . All abovementioned studies focused on the regulation of cell polarization and kinase activity of aPKCι, while interestingly, we found that aPKCι functioned as an antioxidative factor in a kinase-independent manner. Our findings were supported by other studies that aPKCι promoted neuronal differentiation in a manner that did not depend on kinase activity [39] . More importantly, we further demonstrated that this function of aPKCι was involved in drug resistance and cell growth.
Nrf2 has been regarded as one of the main orchestrators of the antioxidant response pathway. For the canonical Keap1-Nrf2 system, also known as "hinge and latch" model, previous studies have reported that Keap1 homodimer interacts with monomeric Nrf2 through DLG and ETGE motifs [40, 41] . This binding model facilitates optimal positioning of the lysine residues between the two ubiquitin-conjugated motifs [23] . The modification of cysteine residues in Keap1 can be induced by oxidative stress, which causes a conformational change of Keap1 that further reduces the ubiquitination and degradation of Nrf2 [42] . On the other hand, accumulating lines of evidence demonstrate that there is cross talk between Keap1-Nrf2 and other proteins, such as PALB2, P62, iASPP2 and DPP3, which can disrupt the normal Keap1-Nrf2 signaling and associate with malignant progression [16, [43] [44] [45] . These proteins can bind with either Keap1 or Nrf2 through Keap1binding motifs (DLG or ETGE motifs). In this study, we found that aPKCι interacted with Keap1 through the DLL motif, a similar set in Nrf2, which is highly conserved from poultry to human in aPKCι. Indeed, we have detected the protein complex of aPKCι-Keap1-Nrf2 in GBC cell lines. Furthermore, aPKCι can elevate Keap1-Nrf2 signaling under both basal conditions and stressed conditions. The data showed that the binding amount of aPKCι and Keap1 was dramatically elevated with the treatment of gemcitabine. It is also noteworthy that increased aPKCι-Keap1 interaction was accompanied by a significant reduction of Keap1-Nrf2 interaction under oxidative stresses. According to the "hinge and latch" model, gemcitabine-induced oxidative stress may modify the specific cysteine residues of Keap1, which leads to conformational change of Keap1 resulting in the dissociation of Nrf2 from Keap1. It is propitious for the binding of aPKCι and Keap1, and consequently, newly synthesized Nrf2 proteins bypass Keap1. These observations indicate that revealing the regulatory mechanisms in the Keap1-Nrf2 system may provide potential opportunities for pharmacological intervention in different cellular conditions.
Although previous studies have reported that phosphorylation of Nrf2 by PKC facilitated the dissociation of Nrf2 from Keap1 [19, 46] , the main enzyme and molecular mechanism underlying the interaction were not investigated. In contrast, the kinase-independent functions of aPKC, including aPKCι, have been reported in multiple signaling pathways [39, [47] [48] [49] . In this study, we have investigated that aPKCι can promote nuclear translocation of Nrf2, but not phosphorylated Nrf2, to activate cytoprotective gene expression. Mechanistically, we constructed a series of mutants to demonstrate how aPKCι disrupts the Keap1-Nrf2 system. Interestingly, we found that aPKCι may act as a "competitive" binder of Keap1. On one hand, Keap1 knockdown has no effect on the expression of aPKCι. Conversely, aPKCι depletion also does not result in the change of Keap1. This suggests that Keap1 is not a substrate of aPKCι. On the other hand, our data show that aPKCι overexpression increased, while knockdown decreased, the protein level of Nrf2. However, the mRNA level of Nrf2 has not significant alteration with aPKCι overexpression or knockdown. Therefore, we speculated that aPKCι might modulate Nrf2 protein did not occur at the transcriptional level. Indeed, we found that aPKCι regulated the protein stability of Nrf2 and inhibited its proteasome-mediated degradation. Although DLG motif is weaker than ETGE motif, both DLG and ETGE motifs are required for the Keap1-dependent degradation of Nrf2. In addition, a recent study has shown that the interaction between Keap1 and Nrf2 is dynamic. It contains two distinct conformations and follows a cycle: "open", in which Nrf2 binds one Keap1 molecule through ETGE, and "closed", in which Nrf2 interacts with the Keap1 dimer through DLG and ETGE [42, 44] . Of note, it has been reported that when the ETGE motif bound with Keap1 singly, Nrf2 would not be ubiquitinated by the E3-ubiquitin ligase [50] . When the conformations changed from an open to a closed, Nrf2 was polyubiquitinated and then subsequently released for degradation by the proteasome [42] . Then, aPKCι will be placed in a better position to bind with the regenerated free Keap1 dimer through the DLL motif, which leads to the newly synthesized Nrf2 accumulation and nuclear translocation. Thus, it is not surprising that aPKCι regulates the Keap1-Nrf2 system by competing with Nrf2.
It is also noteworthy that elevated aPKCι expression was further confirmed in human gallbladder cancer specimens. Although lack of high throughput sequencing data, our results showed that the upregulation of Nrf2 protein and its target genes may be at least in part dependent on the elevation of aPKCι in GBC samples. The overexpression of aPKCι significantly correlates with poor prognosis in patients with GBC. Furthermore, it is widely accepted that sustained increase in ROS leads to develop chemoresistance, which may be presumably due to the abnormalities of the Keap1-Nrf2 pathway. Importantly, elevated aPKCι can induce drug resistance in GBC cell lines, indicating that aPKCι may be a potential and an attractive therapeutic target for GBC. However, whether aPKCι modulates mitochondrial ROS in a similar or distinct manner is yet to be delineated. Further studies are required to understand how to target the aPKCι-Keap1-Nrf2 pathway to improve the efficacy of treatment for GBC.
In conclusion, our study demonstrated the importance of elevated aPKCι in promoting the tumorigenesis and gemcitabine resistance through competitive interaction with Nrf2 for binding to Keap1 in GBC cells. Accordingly, our findings expand our knowledge of the functions of aPKCι in cancer, especially its role as an anti-ROS factor is kinaseindependent. These results provide important insights into the development of new, effective therapeutic approaches to overcome drug resistance for the treatment of GBC. Fig. 8 . Schematic summary of how aPKCι induces ROS inhibition and promotes cell tumorigenesis and gemcitabine resistance in GBC. aPKCι competes with Nrf2 for binding to Keap1, which leads to Nrf2 nuclear accumulation and activation of its target genes; this ultimately induces ROS inhibition, tumor growth, and drug resistance.
